Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Shares Outstanding (Weighted Average) (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Shares Outstanding (Weighted Average) for 17 consecutive years, with $55.8 million as the latest value for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 645.47% to $55.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $55.8 million through Jan 2026, up 645.47% year-over-year, with the annual reading at $7.3 million for FY2025, 23.5% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $55.8 million at PharmaCyte Biotech, up from $6.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $55.8 million in Q1 2026, with the low at $6.8 million in Q4 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $15.2 million, with a median of $10.8 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 361279.91% in 2022, then tumbled 57.42% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $20.6 million in 2022, then crashed by 57.42% to $8.8 million in 2023, then decreased by 11.56% to $7.8 million in 2024, then dropped by 12.33% to $6.8 million in 2025, then skyrocketed by 721.39% to $55.8 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $55.8 million, $6.8 million, and $19.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.